MonroyG, Picón-CésarMJ, García-AlemánJ, et al.Glycemic control across the menstrual cycle in women with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: The 780MENS prospective study. Diabetes Technol Ther, 2025; 27(5):395–401; doi: 10.1089/dia.2024.0522
2.
ElhenawyYI, Abdel KaderMS, ThabetRA. Performance of the MiniMed 780 G system on mitigating menstrual cycle‐dependent glycaemic variability. Diabetes Obes Metab, 2024; 26(11):4916–4923; doi: 10.1111/dom.15891
3.
LevyCJ, O’MalleyG, RaghinaruD, et al.; iDCL Trial Research Group. Insulin delivery and glucose variability throughout the menstrual cycle on closed loop control for women with type 1 diabetes. Diabetes Technol Ther, 2022; 24(5):357–361; doi: 10.1089/dia.2021.0431
4.
Bahillo-CuriesesP, Fernández VelascoP, Pérez-LópezP, et al.Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems. Endocrine, 2024; 86(2):539–545; doi: 10.1007/s12020-024-03881-6
5.
CastañedaJ, ArrietaA, van den HeuvelT, et al.Time in tight glucose range in type 1 diabetes: Predictive factors and achievable targets in real-world users of the MiniMed 780G system. Diabetes Care, 2024; 47(5):790–797; doi: 10.2337/dc23-1581
6.
HamidiV, PettusJH. Time in tight range for patients with type 1 diabetes: The time is now, or is it too soon? Diabetes Care, 2024; 47(5):782–784; doi: 10.2337/dci23-0092
7.
LinG, SiddiquiR, LinZ, et al.Blood glucose variance measured by continuous glucose monitors across the menstrual cycle. NPJ Digit Med, 2023; 6(1):140; doi: 10.1038/s41746-023-00884-x
